Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan (Q44562612)

4 December 2017

title

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan (English)

1 reference

B-cell non-Hodgkin lymphoma

4 December 2017

1 reference

1 reference

1 reference

3

1 reference

4 December 2017

Thomas E Witzig

1

1 reference

4 December 2017

Arturo Molina

2

1 reference

4 December 2017

Christos Emmanouilides

4

1 reference

4 December 2017

Russell J Schilder

5

1 reference

4 December 2017

Ian W Flinn

6

1 reference

4 December 2017

Mohamed Darif

7

1 reference

4 December 2017

Roger Macklis

8

1 reference

4 December 2017

Katie Vo

9

1 reference

4 December 2017

Gregory A Wiseman

10

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

4 December 2017

1 reference

4 December 2017

volume

109

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1804-1810

1 reference

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

Radioimmunotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22617

7 January 2021

Identifiers

DOI

10.1002/CNCR.22617

1 reference

release_drv6f2t5onbibalxsloeuflcdu

4 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/drv6f2t5onbibalxsloeuflcdu

24 November 2022

mapped directly with Wikidata item

1 reference